How Climaco was paid
$1.1M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Total |
|---|---|---|---|---|
| John ClimacoChief Executive Officer | $525,000 | $292,817 | $285,863 | $1,103,680 |
| Christopher DownsChief Financial Officer | $340,000 | $146,410 | $134,640 | $621,050 |
| Sandra SilbermanChief Medical Officer | $200,000 | $73,205 | $88,436 | $361,641 |
What changed and why
- $1.1M$1,103,680 CEO total compensation in 2024, up from $624,348 in 2023.
- $293K$292,817 CEO option awards represented the largest 2024 equity component.
- 99%99% of potential bonuses were awarded to Climaco and Downs for 2024.
- 99.5%99.5% of potential bonus was awarded to Silberman for 2024.
- 50%50% was Climaco’s target bonus percentage; Downs and Silberman each had 40% targets.
- 17,082 options were granted for 2024 service, subject to stockholder approval.
Other CNS Pharmaceuticals proxy statements
- 2026 proxy statement
John Climaco paid $1.2M (+6% on the year).
Filed Aug 21, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.